PharmaCyte Biotech, Inc. Uncategorized Contracts & Agreements

30 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Engagement Letter, dated May 9, 2023 by and between Synaptogenix, Inc. and Katalyst Securities LLC
PharmaCyte Biotech, Inc.
2023
Form of Director Offer Letter
PharmaCyte Biotech, Inc.
Biotechnology
NV
2022
Description of Securities
PharmaCyte Biotech, Inc.
Biotechnology
2022
Description of Securities
PharmaCyte Biotech, Inc.
Biotechnology
2021
Amendment No. 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated July 15, 2020
PharmaCyte Biotech, Inc.
Biotechnology
CA
2020
Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated May 4, 2020
PharmaCyte Biotech, Inc.
Biotechnology
2020
Second Amendment to Licensing Agreement between the Company and Austrianova Singapore Pte. Ltd. effective May 14, 2018
PharmaCyte Biotech, Inc.
Biotechnology
2018
Third Amendment to Licensing Agreement between the Company and Austrianova Singapore Pte. Ltd. effective May 14, 2018
PharmaCyte Biotech, Inc.
Biotechnology
2018
Letter Agreement between the Company and Dr. Tong dated October 9, 2017
PharmaCyte Biotech, Inc.
Biotechnology
CA
2017
[Signaturepage follows]
PharmaCyte Biotech, Inc.
Biotechnology
CA
2017
[Signature page to follow]
PharmaCyte Biotech, Inc.
Biotechnology
CA
2017
23046 Avenida de la Carlota| Suite 600 | Laguna Hills | California 92653 Office: 917 ###-###-#### |Fax: 917 ###-###-#### | Mobile: 917 ###-###-#### | ***@***
PharmaCyte Biotech, Inc.
Biotechnology
2017
FOURTHSTOCK OPTION AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
NV
2017
ThirdSTOCK OPTION AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
NV
2017
FOURTHSTOCK OPTION AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
NV
2017
AMENDMENT NO. 2 TO EXECUTIVECOMPENSATION AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
NV
2017
AMENDMENT NO. 2 TO EXECUTIVE COMPENSATIONAGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
NV
2017
CHARDAN CAPITAL MARKETS
PharmaCyte Biotech, Inc.
Biotechnology
2016
First Amendmentto Licensing Agreement
PharmaCyte Biotech, Inc.
Biotechnology
2016
SecondAmendment toLicensingAgreement
PharmaCyte Biotech, Inc.
Biotechnology
2016
First Amendment toLicensing Agreement
PharmaCyte Biotech, Inc.
Biotechnology
2016
AMENDMENT NO. 1 TO EXECUTIVE COMPENSATIONAGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
2016
AMENDMENT NO. 1 TO EXECUTIVE COMPENSATIONAGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
2016
12510 Prosperity Drive | Suite 310 | SilverSpring | Maryland 20904-1643 Office: 917 ###-###-#### | Fax: 917 ###-###-####| Mobile: 917 ###-###-#### | ***@***
PharmaCyte Biotech, Inc.
Biotechnology
MD
2015
ExecutiveCompensation AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
MD
2015
ExecutiveCompensation AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
MD
2015
Licensing Agreement
PharmaCyte Biotech, Inc.
Biotechnology
2014
MANUFACTURING FRAMEWORK AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
2014
Licensing Agreement
PharmaCyte Biotech, Inc.
Biotechnology
2013
REAL ESTATE SALE AGREEMENT
PharmaCyte Biotech, Inc.
Biotechnology
2010